Global Health & Medicine
Online ISSN : 2434-9194
Print ISSN : 2434-9186
Current state and prospect of the perioperative strategy for non-small cell lung cancer
Hiroshi TakumidaYuichiro TakedaGo Naka
Author information

2021 Volume 3 Issue 1 Pages 24-30


This paper provides an overview of perioperative treatment for non-small cell lung cancer (NSCLC), including the current widespread use of cytotoxic anticancer agents, promising molecular targeted agents, and immuno-checkpoint inhibitors. Multiple clinical trials have confirmed that postoperative chemotherapy with cytotoxic anticancer agents should be given for stage IIB to III (according to the 8th edition of the TNM classification for NSCLC) if possible, and preoperative treatment also is recommended for patients with N2 or higher stage. However, advances in concurrent chemoradiotherapy are expected to change the significance of neoadjuvant therapy. Perioperative treatment with molecular targeted agents appears to extend disease-free survival, but there is currently no evidence that it can extend overall survival. Perioperative treatment with immune checkpoint inhibitors requires further evidence but is likely to be effective. Although perioperative treatment of NSCLC could be costly it continues to evolve in hopes of a cure.

Information related to the author
© 2021 National Center for Global Health and Medicine
Previous article Next article